Table 4. Univariate and multivariate analysis of time to progression (log-rank test) for oxaliplatin-based chemotherapy.
| Univariate analysis | |||
|---|---|---|---|
| Clinical parameter | n | Median time to progression (months) | p value |
|
Age |
|
|
|
| < 75 y |
47 |
10 |
0.9252 |
| ≥ 75 y |
2 |
- |
|
|
Gender |
|
|
|
| Male |
25 |
11 |
0.6149 |
| Female |
24 |
9.7 |
|
|
Primary tumor localization |
|
|
|
| Sigmoid colon |
24 |
11.6 |
0.2375 |
| Colon/Rectum |
25 |
9 |
|
|
WHO performance status |
|
|
|
| · 0–1 |
49 |
10 |
0.3185 |
| · 2–3 |
0 |
- |
|
|
Histological type |
|
|
|
| Tubular |
22 |
13 |
0.0462 |
| Others |
27 |
9 |
|
|
Pretreatment CEA level (ng/ml) |
|
|
|
| · ≤ 5 |
25 |
13 |
0.0084 |
| · > 5 |
21 |
8 |
|
|
Resection of metastases |
|
|
|
| Yes |
18 |
16 |
0.0226 |
| No | 31 | 9 | |
| Multivariate analysis | |||
|---|---|---|---|
|
Clinical parameter |
HR (95% CI) |
p value |
|
| Histological type |
NS |
> 0.05 |
|
| Tubular vs. others |
|
|
|
| Resection of metastases vs. no resection of metastases |
0.43 (0.21–0.90) |
0.0249 |
|
| K-Ras gene mutation |
0.49 (0.24–0.99) |
0.0451 |
|
| mutation vs. wild-type |
|
|
|
| Pretreatment CEA level (ng/ml) |
NS |
> 0.05 |
|
| ≤ 5 vs. > 5 | |||
NS, not significant.